PD-L1 and VEGF — Drug Target

All drugs that target PD-L1 and VEGF — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

PD-L1 inhibitor + VEGF inhibitor combination

Phase 3 pipeline (1)

• Atezolizumab & Bevacizumab · IRCCS Azienda Ospedaliero-Universitaria di Bologna · PD-L1 inhibitor + VEGF inhibitor combination · Oncology
  Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control.

Phase 2 pipeline (1)

• Aatezolizumab plus Bevacizumab · Tae Won Kim · PD-L1 inhibitor + VEGF inhibitor combination · Oncology
  Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.